Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GNPX vs REGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REGN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

REGN Overall Winner 6-Pillar Tally: GNPX 0 – 6 REGN Matrix Metrics: GNPX 0 – 10 REGN

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas REGN carries 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin).

  • Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GNPX vs REGN
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48
REGN NASDAQ Head-to-Head Winner
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
TTM Revenue $16.9B
Forward P/E 14.8x
Beta / 30D Vol 0.30β · 55% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 57
RSI-14: 57.2 · SMA20: $912.90 · SMA50: $829.76

6-Pillar Scorecard Institutional Category Breakdown (GNPX 0 – 6 REGN)

Columns: Metric · GNPX · REGN
1. Valuation Multiples REGN
Forward P/E N/M 14.8x
Trailing P/E N/M 20.4x
PEG Ratio N/M 1.15x
EV / Revenue N/M 5.6x
2. Growth & Scale REGN
Revenue Growth (YoY) +0.0% +36.3%
Earnings Growth (YoY) +0.0% +35.5%
TTM Revenue (USD) N/A $16.9B
Market Cap $2.2M $95.5B
3. Profitability & Quality REGN
Gross Margin N/A 46.7%
Operating Margin 0.0% 30.4%
Net Profit Margin 0.0% 28.5%
Return on Equity (ROE) -233.7% 14.9%
4. Balance Sheet & Cash Flow REGN
Cash Generation (TTM) N/A $3.63B
Cash Flow Margin N/A 21.5%
Net Cash / Leverage $11.26 Book/Sh · -233.7% ROE $952M Net Cash
Dividend Yield None (0.00%) 0.39%
5. Options & Positioning REGN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 39.4% (6th %ile)
Put/Call OI Skew N/A 0.58x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat REGN
OpEx & R&D Intensity N/A 16.3% of Rev ($2.75B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GNPX (0) vs REGN (10)
Institutional Metric GNPX REGN Criterion Row Edge
Market Capitalization
Scale
$2.2M $95.5B Larger Scale REGN
Trailing P/E Ratio
Valuation
N/M 20.4x Lower Multiple REGN
Forward P/E Ratio
Valuation
N/M 14.8x Lower Multiple REGN
Revenue Growth (YoY)
Growth
+0.0% +36.3% Higher Growth REGN
Operating Margin (TTM)
Profitability
0.0% 30.4% Higher Margin REGN
Net Profit Margin
Profitability
0.0% 28.5% Higher Margin REGN
Return on Equity (ROE)
Capital Efficiency
-233.7% 14.9% Higher ROE REGN
52-Week Range Position
Momentum
11% ($0–$10) 82% ($592–$992) Stronger Trend REGN
Beta / 30D Volatility
Risk Regime
-4.68β · 96% Vol 0.30β · 55% Vol Lower Realized Risk REGN
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite REGN
Trailing 12M Revenue (USD)
Operating Scale
N/A $16.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.15x PEG · 5.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.26 Book/Sh · -233.7% ROE) $3.63B ($952M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REGN +39.17 pp
GNPX: -26.77% · REGN: +12.4%
3M Horizon REGN +75.06 pp
GNPX: -63.93% · REGN: +11.13%
6M Horizon GNPX +32.48 pp
GNPX: +76.59% · REGN: +44.11%
1Y Horizon REGN +87.6 pp
GNPX: -56.59% · REGN: +31.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs REGN. Trailing 12-month operating profitability (GNPX 0.0% vs REGN 30.4%) and valuation multiples (GNPX N/M vs REGN 14.8x Forward P/E) are benchmarked directly in Pillar 4 below.

GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M
REGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16.9B
Gross Margin46.7%
Op. Margin30.4%
ROE / Fwd P/E14.9% · 14.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REGN CONSOLIDATION
56d in phase · OBV DISTRIBUTION
Current IV 39.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.58x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact REGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $952.40 · IV 33.5%

REGN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($95,240)

Compare $95,240 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 33.5% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $950 / $1,000 Bull Call Spread

Buy 1x $950C · Sell 1x $1,000C · 31d

Net Entry $2,387 Debit
T+5d @ +5% Move +$891 (+37%)
Max Risk / Buffer $2,387 Capped
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $880 / $820 Bull Put Spread

Sell 1x $880P · Buy 1x $820P · 59d

Net Entry $1,367 Credit
Max Credit / Yield +$1,367 (+29.5% RoM)
Max Risk / Buffer -9.0% Cushion ($4,633 Mgn)
5d Edge & Liquidity 75% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $880P / $960-$1,040C Seagull

Sell 1x $880P · Buy 1x $960/$1,040C · 31d

Net Entry $1,185 Debit
T+5d @ +5% Move +$2,220 (+15.8% RoM)
Max Risk / Buffer -7.6% Put Cushion ($14,093 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REGN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $95.5B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment 16.3% of Rev ($2.75B)
90D Engineering Disclosures 0 Published

Investor FAQ GNPX vs REGN Key Questions & Quantitative Answers

As of Nov 20, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas REGN carries 46.0/100 (HOLD) at $920.69 (14.8x Forward P/E, 30.4% operating margin). Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile REGN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

REGN leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus $16.9B for REGN. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.

REGN screens cheaper on headline valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REGN trades at 14.8x Forward P/E, 20.4x Trailing P/E, 1.15x PEG, and 5.6x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus REGN (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, REGN carries 39.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.58x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.